Evidence map›Paper›PMID 41428121›Full record

ArticleEuropean radiology experimental2025

Immunomodulatory effect of ultrasound-guided cryoablation in early breast cancer: pilot study on blood and surgical samples.

Federica Pediconi, Francesca Galati, Marianna Nuti, Veronica Rizzo, Andrea Botticelli, Lucrezia Tuosto, Angelica Pace, Aurelia Rughetti, Giulia d'Amati, Bruna Cerbelli and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European radiology experimental, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Federica Pediconi *Department of Radiological, Oncological, and Pathological Sciences, Sapienza University of Rome, Rome, Italy.
Francesca Galati *Department of Radiological, Oncological, and Pathological Sciences, Sapienza University of Rome, Rome, Italy.
Marianna NutiLaboratory of Tumor Immunology and Cell Therapies, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Veronica RizzoDepartment of Radiological, Oncological, and Pathological Sciences, Sapienza University of Rome, Rome, Italy. veronica.rizzo@uniroma1.it.ORCID http://orcid.org/0000-0003-1781-3174
Andrea BotticelliDepartment of Radiological, Oncological, and Pathological Sciences, Sapienza University of Rome, Rome, Italy.
Lucrezia TuostoLaboratory of Tumor Immunology and Cell Therapies, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Angelica PaceLaboratory of Tumor Immunology and Cell Therapies, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Aurelia RughettiLaboratory of Tumor Immunology and Cell Therapies, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.
Giulia d'AmatiDepartment of Radiological, Oncological, and Pathological Sciences, Sapienza University of Rome, Rome, Italy.
Bruna Cerbelli *Department of Radiological, Oncological, and Pathological Sciences, Sapienza University of Rome, Rome, Italy.
Chiara Napoletano *Laboratory of Tumor Immunology and Cell Therapies, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy.

Funding

Sapienza Università di Roma RM12117A7B767D0DSapienza Università di Roma RM1221816BC0EAASapienza Università di Roma RM123188C3F3E706Sapienza Università di Roma RP122181610A7266
6 · The paper itself

Abstract

objectiveCryoablation, a minimally invasive, image-guided procedure, induces tumor necrosis through freezing/thawing cycles. This pilot study investigates the immunomodulatory effects of cryoablation in early breast cancer (BC) patients by analyzing blood and surgical samples, with a focus on T-cell subsets, regulatory T cells (Tregs), serum cytokines, and high-mobility group box 1 (HMGB1) levels. MATERIALS AND

methodsTen patients with early BC (cT1 cN0) underwent ultrasound-guided cryoablation using a cryoablation system followed by surgical resection. Peripheral blood mononuclear cells were isolated at four time points: pre-ablation (T0), day 2-3 (T1), 2-3 weeks post-ablation (T2), and post-surgery (T3). Immune cell populations, including Tregs and activated CD137

resultsCryoablation significantly increased circulating HMGB1 levels at T1 (p = 0.047), with further elevation post-surgery (p = 0.023), suggesting immune activation. CD137

conclusionCryoablation induces significant immunological changes, including the release of HMGB1, modulation of CD137 RELEVANCE STATEMENT: Cryoablation triggers immune activation in early BC, as indicated by increased CD137 KEY POINTS: Cryoablation is a promising nonsurgical treatment for early-stage BC. The procedure may induce immune activation by increasing HMGB1 and modulating T-cell populations. Tregs appear to decrease after cryoablation, suggesting immunomodulatory potential. Histopathology confirms effective tumor ablation in most treated patients. Cryoablation shows immunomodulatory effects and may provide a rationale for future combination with immunotherapy.

Indexed as

Breast NeoplasmsCryosurgeryUltrasonography, InterventionalAdultAgedCytokinesFemaleHMGB1 ProteinHumansMiddle AgedPilot ProjectsT-Lymphocytes, RegulatoryCytokinesHMGB1 ProteinBreast neoplasmsCryoablationHMGB1 proteinMinimally invasive proceduresRegulatoryT-lymphocytes

Identifiers

PMID41428121
PMCPMC12722633

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.